Thomas Richardson
About Thomas Richardson
Thomas Richardson is a Biomaterials Engineer currently working at Pear Bio, where he specializes in in vitro models for disease modeling and drug discovery. He has a strong background in bionanotechnology, holding a Master's degree from the University of Leeds and a PhD from the University of Bristol.
Work at Pear Bio
Thomas Richardson currently serves as a Biomaterials Engineer at Pear Bio, a position he has held since 2021. In this role, he focuses on the development of in vitro models for disease modeling and drug discovery. His work emphasizes the use of 3D hydrogels and 3D bioprinting technologies. Additionally, he has contributed to the research and development of Pear Bio's microfluidic chip platform, which plays a crucial role in the company's clinical trial programs.
Education and Expertise
Thomas Richardson has an extensive educational background in nanotechnology and biomaterials. He earned a Doctor of Philosophy (PhD) in Functional Nanomaterials from the University of Bristol, where he studied from 2015 to 2020. Prior to this, he obtained a Master’s Degree in Bionanotechnology from the University of Leeds in 2015. His undergraduate studies culminated in a Bachelor of Science (B.Sc.) in Nanotechnology from the University of Leeds, completed in 2014. His academic training supports his expertise in innovative problem-solving in scientific research.
Background
Thomas Richardson's professional experience includes a range of roles in scientific research and development. He worked as a Scientist focusing on Fibrosis at Engitix Therapeutics for six months in 2020 in London. Prior to that, he was a Postgraduate Researcher at the University of Bristol from 2019 to 2020. He also gained experience as a Project Intern at CELLINK in Gothenburg, Sweden, in 2018. His diverse background contributes to his strong emphasis on developing new assays and delivering time-critical data in his current role.
Achievements
Throughout his career, Thomas Richardson has made significant contributions to the field of biomaterials and nanotechnology. His work on the microfluidic chip platform at Pear Bio is integral to advancing clinical trial programs. His focus on innovative problem-solving has led to the development of new assays, enhancing the efficiency of scientific research. His academic achievements, including a PhD and Master's degree, further underscore his commitment to advancing knowledge in his field.